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Abstract 
Photodynamic cancer therapy (PDT) is a type of treatment involving the use of 
light in conjunction with a photosensitive agent- a chemical or series of chemicals 
designed for activation when exposed to light. This research project investigated the 
synthesis and identification of the novel photosensitive agent, H2TPP-Pro-OH. To create 
the water-soluble porphyrin, (S)-(+)-prolinol was reacted with the tetra-carboxyl 
porphyrin, H2TPPC, to form the final H2TPP-Pro-OH product. This compound was then 
purified using syringe filtration and column chromatography, and subsequently 
characterized using infrared (IR), nuclear magnetic resonance (NMR), and Ultraviolet-
visible (UV-vis) spectroscopies, as well as High Performance Liquid Chromatography 
(HPLC). Finally, the utility of the material as a PDT agent was determined by examining 
the cytotoxicity of the H2TPP-Pro-OH product using an MTT assay on MDA-MB-231 
triple negative breast cancer (TNBC) cells comparing dark and light exposure. 
 
Background 
What is Photodynamic Therapy? 
 Photodynamic Therapy (PDT) is a way to treat cancer using light and a 
photosensitive compound (Figure 1). When the photosensitive agent is injected into the 
patient, it is “activated by light of a specific wavelength,” which can cause three 
outcomes. Primarily, a reactive oxygen species, known as an oxygen free radical, can 
form which then destroys the surrounding tumorous cancer cells2. In addition to 
destroying the cancer cells via a reactive oxygen species, the activation of the 
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photosensitive agent can “destroy the blood vessels that feed the cancer cells,” and 
finally, the activation can “[alert] the immune system to attack the cancer”3. 
 
               
Why PDT? 
Normal breast cancer cells (Figure 2) have receptors for estrogen, progesterone, 
and HER2 hormones, but triple negative breast cancer (TNBC) cells (Figure 3) lack 
these receptors, so these cells are unable to be treated in the same way as normal 
Figure 2. A type of normal 
breast cancer cells, containing 
receptors for estrogen and 
progesterone.4  
Figure 3. A triple negative 
breast cancer (TNBC) cell, 
lacking receptors for 
estrogen, progesterone and 
HER2.5 
Figure 1. (a) A patient diagnosed with a tumor is injected with a photosensitizer. (b) 
Due to the nature of the photosensitizer, it collects in the tumor over time. (c) The 
tumor is exposed to light for a given amount of time at a given wavelength of light, 
activating the photosensitizer. (d) The tumor is selectively destroyed.1 
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breast cancer cells due to the lack of receptors. TNBC cells are the cause for ten to 
twenty percent of breast cancer cases6. These cells are more likely to spread and recur, 
and they give the affected person an average survival rate of less than five years. 
Unfortunately, TNBC cells do not respond to chemotherapy or radiation in the same way 
that normal breast cancer cells respond. One method of treatment for TNBC that is 
being explored is Photodynamic Therapy (PDT). Through testing with PDT, the efficacy 
of the porphyrin compound H2TPP-Pro-OH on the treatment TNBC cells can be 
concluded. 
What are Porphyrins? 
 Porphyrin molecules are most known for their role in the active site of 
hemoglobin, the blood oxygen transporter of the body. An organic porphyrin ring is the 
basis for the formation of the heme group, the “non-protein active site within myoglobin 
and hemoglobin”7. Regarding PDT, however, porphyrin photosensitizers are one of the 
three main functional elements of the process. The other two main functional elements 
of the PDT process are ensuring an optimal wavelength of light, and ensuring the 
formation of singlet, molecular oxygen8.  
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A porphyrin is a large ring molecule containing four pyrrole groups connected by 
single and double bonds (Figure 4). The alternating single and double bonds give 
aromaticity and stabilization. Porphyrin molecules are ideal for PDT because of their 
likeliness to accumulate in tumor tissue. Most tumors contain “highly perfused areas” 
allowing for greater blood flow in the tumor than in an area with healthy, non-tumorous 
cells10. When the photosensitive porphyrin is injected into the body, it travels throughout 
the body via the blood, but because tumors have greater blood flow, the porphyrin 
molecules are more likely to gather in the tumor. Furthermore, when activated by light, 
porphyrin photosensitizers are able to create singlet, molecular oxygen, which results in 
cytotoxicity of the tumor tissue cells11.  
 
Photodynamic Therapy Used in Oral Treatment 
Malignant tumors that develop in “the oral cavity, the pharynx, the nasal cavity, 
and the larynx” (Figure 5) are categorized as head and neck cancer, or squamous cell 
carcinoma (SCC), and are seen to be caused by age, sunlight, alcohol abuse, and 
Figure 4. The structure of a porphyrin 
molecule. Chemical formula C20H14N4.9  
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smoking or other tobacco use13. Some symptoms associated with SCC include a white 
or red patch on the gums or tongue (oral cavity), trouble breathing or speaking 




Photodynamic Therapy has recently begun an upward trend to its effectiveness 
in destroying head and neck cancer. The three photosensitizers currently being used in 
testing are Photofrin®, Foscan®, and 5-Aminolevulinic acid (ALA)13. 
 
Photofrin® 
Photofrin® (Figure 6) is the most studied photosensitive agent and has 
“generally excellent” clinical results due to its reliability, easy activation, and non-toxic, 
pain-free administration, but it has shown to not be highly selective at 2 mg/kg (normal 
injection) and demonstrates “significant prolonged skin photosensitivity” for up to six 
Figure 5.  Oral Cavity Anatomy12 
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weeks after initial administration13. The prolonged skin sensitivity observed with 
Photofrin® is due to it being a first-generation PDT agent, meaning that it lacks long 
wavelength absorption and thus the activating light does not penetrate deeply into the 





The second photosensitive agent being explored in the treatment of head and 
neck cancer is Foscan® (Figure 7). Foscan® is a second-generation PDT agent that 
provides “greater tumor selectivity and deeper light penetration… with the use of longer 
wavelengths of activating light” when compared to first-generation photosensitizers such 
as Photofrin®18. Foscan® is injected at 0.15 mg/kg and is activated by laser lights at 
652 nm13. While Foscan® has shown at least 93% efficacy in patients with 
oropharyngeal cancer, this photosensitizer has only been approved for use in Europe13. 
Figure 6. Photofrin® (Porfimer Sodium) Structure15 






Though it has limited light penetration ability at 635 nm, and is restricted to 
superficial lesions, 5-Aminolevulinic acid (ALA) (Figure 8) is a promising photodynamic 
cancer therapy agent13. ALA administered topically and orally “has been used for the 
treatment of pre-malignant and malignant lesions in the oral cavity” and has been 
proven to “rapidly” clear from the body within 48 hours, with skin sensitivity lasting “less 
than 24 hrs”13. Among patients treated for oral dysplastic lesions, there was a 100% 
success rate in the “regression of the lesions to normal or less dysplastic”13. 
Unfortunately, due to its limited light penetration, ALA is not effective in the destruction 
of deep tumors. 
Figure 7. Foscan® Structure17 






Other Clinical Applications of Photodynamic Therapy 
 Though PDT is actively being explored as a method of treatment to cure 
diseases of the oral cavity, its other clinical applications have made significant progress 
as well. The photosensitizer Photofrin® has been FDA approved for the treatment of 
obstructive esophageal cancer and early esophageal cancer. By using PDT, dysphagia 
was relieved in both types of cancer, and in early esophageal cancer, “72% of PDT 
patients showed complete elimination” of high-grade dysplasia20. Photofrin® has also 
shown positive results in the treatment of microinvasive non-small cell lung cancer. 
Treatment has resulted in a “79% complete response” of early lung cancer and an 
average of a 51% response rate of late stage lung cancer20. In addition to this, ALA and 
Photofrin® have been used in the treatment of skin cancer with the ALA showing a 64% 
complete response rate and “excellent cosmetic results” after three years of treatment20. 
The newest clinical trials being performed are aiming to see positive results in the 
Figure 8. 5-Aminolevulinic acid (ALA); precursor 
to Protoporphyrin IX (PpIX)19 
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treatment of age-related macular degeneration and coronary heart disease. No clinical 
results of these trials have been published.  
 
Introduction to Project 
 As shown above, photodynamic therapy is currently being explored as a method 
to treat different types of cancer, including breast cancer. This project aimed to create a 
novel, water-soluble photosensitive agent that could destroy triple negative breast 
cancer cells using PDT. This was achieved using a porphyrin molecule, the backbone of 
the final product, H2TPP-Pro-OH. 
Methods 
Porphyrin Synthesis 
The amine used to create the novel porphyrin was (S)-(+)-prolinol. Water 
solubility was a critical factor in the synthesis of the molecule because, when 
administered, PDT agents are injected into the bloodstream. The concentration of water 
in the blood is approximately 92%, meaning that it is vital for the photodynamic therapy 
agent to be water soluble. 
Formation of H2TPPC, (3) 
To create the final water-soluble product, the starting material 5, 10, 15, 20-
tetrakis(4-carboxyphenyl) porphyrin, or H2TPPC (3), was first synthesized (Figure 9). 
The material (3) was synthesized by adding 3.00 g of 4-carboxybenzaldehyde and 1.4 
mL of pyrrole to a 500 mL round bottom flask containing approximately 200 mL of 
propionic acid and a stir bar. The flask was then completely wrapped in aluminum foil, to 
prevent any possible light sensitive reactions from producing extra side products, and 
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the mixture was allowed to reflux for an hour. Afterward, the heat was removed allowing 
the solution to cool. Once cooled, the flask was covered with parafilm and placed in a 
freezer overnight at -20°C.  
Next, vacuum filtration was performed on the newly formed H2TPPC by attaching 
a medium sintered glass funnel to a filter flask. Once the product had been filtered, 
CH2Cl2 was added to the round bottom flask to obtain any additional product. After all of 
the product had been vacuum filtered, the solid H2TPPC (3) was scraped into a vial and 
dried overnight.  
 
 
Formation of the Acid-Chloride Porphyrin, (4) 
Once the H2TPPC had been synthesized, the acid-chloride intermediate (4) was 
able to be synthesized (Figure 10). This reaction began by dissolving 0.25 g of H2TPPC 
(3) in approximately 20 mL of dry dimethylformamide (DMF) in a clean, oven dried, 100 
mL round bottom flask. While stirring, the flask was put under the constant flow of 
Figure 9. Reaction 1. 4-formylbenzoic acid (2) reacts with pyrrole (1) in propionic acid to 
form H2TPPC (3). 
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nitrogen. When the flask had been effectively flooded with nitrogen, a 1 mL syringe was 
used to retrieve 0.25 mL of SOCl2 (thionyl chloride) which was quickly added to the 100 
mL round bottom flask via a rubber septum.  
After the reaction had been stirred under the flow of nitrogen for an hour, the 
DMF was removed by evaporation and the flask placed under vacuum overnight.  
 
 
Formation of the Final Product, H2TPP-Pro-OH, (5) 
In order to form the final H2TPP-Pro-OH product (5) (Figure 11), 0.30g (S)-(+)-
prolinol was added to an oven dried vial and then dissolved in freshly distilled methanol. 
This solution was mixed and then transferred into the round bottom flask containing the 
acid-chloride porphyrin (4) intermediate. The flask was again wrapped in aluminum foil 
to eliminate any light dependent reactions and placed under the constant flow of 
nitrogen. After stirring for one hour the methanol was removed under reduced pressure.   
Figure 10. Reaction 2. H2TPPC (3) reacts with thionyl chloride (SOCl2) in dimethylformamide 
(DMF) to form the acid chloride porphyrin, H2TPPCl (4). 





To purify the H2TPP-Pro-OH (5), the process began by adding a small amount of 
50/50 methanol/water to the round bottom flask containing the water-soluble porphyrin 
until it dissolved. Next, a syringe filter was used to filter the product into a 100 mL 
beaker. Using a Pasteur pipette, half of this product was added in a swirling motion to a 
chromatography column packed with Sephadex LH-20, then eluted with 50/50 
methanol/water in the chromatography column (Figure 12). Chromatography removes 
impurities from the desired product. After all of the desired porphyrin-colored product 
had been collected from the LH-20 chromatography column, the product was 
rotavapped and then placed under vacuum to dry overnight.  
Figure 11. Reaction 3. The acid chloride porphyrin (4) is reacted with the amine, (S)-
(+)-prolinol, in distilled methanol to form the final product, H2TPP-Pro-OH. 
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In order to ensure purification, the material was run 
through a second Sephadex G-50 chromatography column using 
Milli-Q water as the eluent. First, Milli-Q water was added to the 
round bottom flask containing the product that had previously 
been purified through the Sephadex LH-20 column and the 
product dissolved. A Pasteur pipette was used to add half of the 
product into the column in a swirling motion, which was then 
eluted with Milli-Q water and allowed to pass through the 
column. Once the impurities had passed through the column, the 
purified product (5) was collected, rotavapped, and this final 
product was evaporated under reduced pressure until dry.  
 
Characterization and Results 
Infrared Spectroscopy 
 Infrared (IR) spectroscopy is a tool used by chemists to 
determine molecular structure based on the fact that functional 
groups absorb infrared light at different wavelengths in accordance to their structure21. 
As a functional group absorbs different energy, it stretches or bends and this 
wavenumber and transmittance is recorded graphically. Based on the percent 
transmittance shown in the figures below, the amine, (S)-(+)-prolinol, (Figure 13) and 
the final porphyrin product (5) (Figure 14) both have a broad -OH stretch at ca. a 
wavenumber of 3300 cm-1 and a C=O double bond stretch at ca. a wavenumber of 1700 
cm-1, while the final porphyrin product, additionally, contains an -NH stretch. These 
Figure 12. Liquid 
chromatography 
column. 
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signals consist of amide I, amide II, and amide III bands, at 1580 cm-1, 1533 cm-1, 1376 






Figure 13. Infrared results for (S)-(+)-prolinol. 
Figure 14. Infrared results for H2TPP-Pro-OH. 
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Ultraviolet-Visible Spectroscopy 
 Ultraviolet-Visible (UV-Vis) Spectroscopy is a tool used in chemistry to determine 
the absorbance of a particular sample. The absorbance, or reflectance, of a particular 
molecule is indicative of the perceived color of the molecule either in the ultraviolet or 
visible spectra. Molecules containing “extensively conjugated pi-electrons” or non-
bonding electrons are able to absorb wavelengths of ultraviolet or visible light, and the 
energies associated with these wavelengths excite the electrons to “higher energy 
orbitals”22. If the electrons are more easily excited, they are able to absorb a longer 
wavelength of light.  To perform UV-Vis spectroscopy, a certain wavelength of light 
passes through a solution, which absorbs this radiation (Figure 15).  
Normally, UV light has wavelengths ranging from 200-400 nm, and visible light 
has wavelengths ranging from 400-800 nm. Characteristically porphyrins have a strong 
absorbance at 415 nm, called the “Söret” band, and a series of satellite absorptions 
from 600 to 800 nm, called the the “fingerprint region.” For this particular porphyrin 
molecule, the Söret band is seen at 414 nm (Figure 16), and the approximate Ɛ values 
for the final compound, including the fingerprint region, are shown in the table below 
(Table 1). 
Figure 15. UV-Vis Spectroscopy diagram 
showing how light is transmitted23. 







1H Nuclear Magnetic Resonance Spectroscopy 
Nuclear Magnetic Resonance Spectroscopy (1H NMR) is a technique used for 
the characterization of organic molecules that contain hydrogen atoms. The sample is 
prepared in an NMR tube and subsequently placed in a magnetic field. Compounds are 
characterized by observing the chemical shifts of the hydrogens in the magnetic field24. 
Based on the location of the signals when comparing the free amine (Figure 17) to 
H2TPP-Pro-OH, it is concluded that the final product contained hydrogen atoms 
characteristic of aromatic rings, hydrogen atoms on the pyrrole ring of the porphyrin, 
and hydrogens associated with (S)-(+)-prolinol (Figure 18).  
Figure 16. UV-Vis results for H2TPP-Pro-OH. 
Table 1. Peaks (nm) and epsilon (ε) values for the UV-vis 
spectroscopy of H2TPP-Pro-OH. Epsilon values calculated 
using Beer’s Law: A= 𝜀c𝑙. 






Figure 18.  Results from 1H NMR spectroscopy of final product,  
H2TPP-Pro-OH, in D2O. 
Figure 17.  Results from 1H NMR spectroscopy of the free amine,  
(S)-(+)-prolinol, in CDCl3. 
P a g e  | 22 
 
High Performance Liquid Chromatography 
 High Performance Liquid Chromatography (HPLC) is a chemical technique used 
to “separate, and identify compounds that are present” in a sample mixture25. The 
material is passed through a column containing an absorbent material using a liquid 
solvent to elute each component of a mixture that interacts differently with the materials 
in the column, thus leading to different elution rates of the components as they flow out 
of the column, separating the designed product from any impurities.  
 The sample was dissolved in Milli-Q H2O and analyzed by HPLC. The HPLC 
analysis was completed using a Waters Nova-Pak C18, 3.9 x 150 mm column, using 
100% acetonitrile as the eluent at a flow rate of 1.00 mL/min. H2TPP-Pro-OH indicated 




















0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50
Figure 19. HPLC results for H2TPP-Pro-OH indicating 98% purity. 
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Testing 
MTT Assay Procedure 
 An MTT assay is a method of measuring cellular metabolic activity, and thus 
determining cell viability26. The viable cells contain an enzyme that reduces the MTT 
reagent to a crystalline product called formazan- the formazan crystals have a vivid 
purple color, which is seen in Figure 20. In this particular MTT assay, MDA-MB-231 
TNBC cells were plated onto two 96-well plates and allowed to culture for approximately 
72 hours. After 72 hours, various concentrations of H2TPP-Pro-OH were added to the 
wells containing the TNBC cells and then placed under different conditions- “dark” and 
“light”. Both plates were wrapped in aluminum foil and set in the incubator, but after 
approximately 24 hours of incubation, the cells in the “light” plate were exposed to white 
light (0.5 J/cm2) for approximately 17.5 minutes, then rewrapped in aluminum foil and 
returned to the incubator for 72 hours. After the final 72 hours of incubation, the 
formazan product was dissolved in DMSO and the plates were scanned via a 
spectrophotometer to quantify the results and determine the cytotoxicity of the H2TPP-
Pro-OH. 
 
Figure 20. MTT assay results after full incubation period. The left plate was entirely 
in dark conditions, while the right plate was exposed to light. The purple color 
indicates living cells. 
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MTT Assay Results 
 As previously stated, MTT assays are used to determine cell viability, and cell 
viability is visibly shown by the vivid purple color on the 96-well plates (Figure 20). An 
MTT assay of H2TPP-Pro-OH on TNBC cells was run twice. The first trial used 
porphyrin concentrations of 1, 3, 10, 30, and 100 µM, and at these concentrations the 
lethal dose to kill 50% of the cells (LD50) was at approximately 60 µM (Figure 21). For 
the second trial, an MTT assay was run again at more narrowed concentrations of 30, 
50, 70, 90, and 110 µM, and the LD50 was seen to be approximately 30 µM (Figure 22). 
  
 
Figure 21. Spectrophotometric MTT assay results for trial one of the light and dark 
96-well plates. The porphyrin concentrations used were 1, 3, 10, 30, and 100 µM  





In conclusion, the novel water-soluble porphyrin, H2TPP-Pro-OH, was 
successfully synthesized and its structure further confirmed by various 
characterizations. IR spectroscopy showed the proper -OH stretch, C=O double bond 
stretch, -NH stretch, and the amide I, II, and III bands. The Söret band seen at 
approximately 414 nm on the UV-vis spectroscopy indicated the presence of a 
porphyrin core. 1H NMR spectroscopy showed that the hydrogen atoms were attached 
at the correct locations, while HPLC proved a 98% purity of the final porphyrin product. 
When exposed to light, the H2TPP-Pro-OH porphyrin killed at least 50% of the 
TNBC cells (LD50) at a porphyrin concentration of 30 µM. When remaining in dark 
conditions, the TNBC cells grew at a normal rate. This data indicates that the H2TPP-
Figure 22. Spectrophotometric MTT assay results for trial two of the light and dark 
96-well plates. The porphyrin concentrations used were 30, 50, 70, 90, and 110 µM  
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Pro-OH porphyrin is more effective in killing TNBC cells when exposed to light than 
other porphyrin molecules, possibly making it a viable PDT agent. To conclude this 
data, further experimentation and trials should be performed. 
 
Future Work 
In the future, a new trial of the novel porphyrin will be tested against TNBC cells 
in an MTT assay using the same concentrations of H2TPP-Pro-OH. Data will be 
collected to determine if these well plates exposed to light have the same 
photocytotoxicity as previously determined in the second trial. Other novel water-soluble 
porphyrin derivatives will also be synthesized to examine their cytotoxicity and to 
determine whether a different porphyrin derivative is more desirable in killing MDA-MB-
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